Cartesian Therapeutics, Inc. · NASDAQ:RNAC
Cartesian Therapeutics — Selecta Biosciences — Q1 2017 Earnings Presentation
17 slides from Cartesian Therapeutics's earnings presentation, May 11, 2017
Slide 1: First Quarter 2017 Conference Call
May 11, 2017 First Quarter 2017 Conference Call
Slide 2: Safe Harbor / Disclaimer
Safe Harbor / Disclaimer 2 Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (“the company”), including without limitation, statements regarding the development of its pipeline, the company's expectations about receiving additional pa
Slide 3: Applying Selecta's Immune Tolerance Platform in Three Core Areas
Applying Selecta’s Immune Tolerance Platform in Three Core Areas 3 IMMUNE TOLERANCE SVP Encapsulated Rapamycin Encapsulating Nanoparticle PLA+PLA-PEG Gene TherapyEnzyme Therapy SVP-Rapamycin’s preclinical, clinical and manufacturing data can be applied across a broad range of product candidates Onco
Slide 4: SEL-212 for the Treatment of Severe Gout
SEL-212 for the Treatment of Severe Gout
Slide 5: SEL-212 Designed to Treat Severe Gout Patients, Addressing an Important Unmet Need
SEL-212 Designed to Treat Severe Gout Patients, Addressing an Important Unmet Need 5 6.8 6.0 Seru m Uric Aci d ( sU A ) Le vel ( in m g/ d L) >6.8 mg/dL: Maximum solubility of uric acid in water; point of crystal formation <6.0 mg/dL: FDA/EMA primary endpoint for gout meds Time Slow clearance of dep
Slide 6: SEL-212 Phase 1/2 Trial Overview
Trial Completion Phase 2 Trial Overview 6 • Patients with symptomatic gout and serum uric acid levels >6 mg/dL • Safety, tolerability and pharmacokinetics of multiple doses of SEL-212 and pegsiticase alone • Reduction of ADA levels • Reduction of serum uric acid levels • Multiple ascending dose coho
Slide 7: Severe Gout is a Rare and Serious Disease with Substantial Unmet Needs
No/not diagnosed tophi Severe Gout is a Rare and Serious Disease with Substantial Unmet Needs 8.3 3.1 5.2 4.7 0.5 US Gout Patients Rx Treated Primary Care, Endo, Nephro, Other Rheum* Gout Patients (million)1 530,000 370,000 Estimated SEL-212 Target Patient Population1 US Gout treated at Rheum Est. S
Slide 8: Oncology
Oncology
Slide 9: LMB-100 Immunotoxin Overview
LMB-100 Immunotoxin Overview • LMB-100: Pseudomonas exotoxin A linked to antibody Fab targeting mesothelin • Currently in Phase 1 clinical trials • Efficacy limited by formation of ADAs Ira Pastan, M.D. Head, Molecular Biology Section National Cancer InstituteLMB-100 Anti-mesothelin Fab Pseudomonas
Slide 10: Clinical Activity of SS1P Precursor to LMB-100 in Mesothelioma
Phase 1 Clinical Activity of SS1P Precursor to LMB-100 in Mesothelioma • ADAs limited number of treatment cycles despite heavy immunosuppressive therapy • Patients that tolerated multiple cycles showed significant anti-tumor responses and “unprecedented” long-term remission Benefit of LMB-100 Precur
Slide 11: Preclinical Data Supports the Promise of SVP-Rapamycin + LMB-100 Combination Therapy
Preclinical Data Supports the Promise of SVP-Rapamycin + LMB-100 Combination Therapy Prevents formation of anti-drug antibodies Restores LMB-100’s anti-tumor response SVP alone does not accelerate tumor growth SVP-Rapamycin LMB-100 T u m o r G r o w t h D a y s s i n c e t u m o r i n o c u l a t i
Slide 12: Gene Therapy
Gene Therapy
Slide 13: Example: Repeat Dosing for Lifelong Treatment
Example: Repeat Dosing for Lifelong Treatment • Selecta’s gene therapy programs are targeting rare and severe metabolic diseases with high mortality • Virtually all MMA patients die by age 35 • About half of patients with UCDs, such as OTC, die by the age of 40 • Early treatment improves outcomes •
Slide 14: Smoking Cessation and Relapse Prevention
Smoking Cessation and Relapse Prevention
Slide 15: Dosing Now Underway in Phase 1 Trial of Nicotine Vaccine for Smoking Cessation
Dosing Now Underway in Phase 1 Trial of Nicotine Vaccine for Smoking Cessation & Relapse Prevention • Program being funded by National Institute on Drug Abuse, part of NIH • SELA-070: Our second-generation vaccine candidate, consisting of nicotine-conjugated nanoparticles encapsulating immune stimul
Slide 16: Q1 Financial Overview
Q1 Financial Overview For the Quarter Ended (In thousands, except share and per share data) March 31, 2017 March 31, 2016 Grant & Collaboration Revenue $137 $2,088 Research & Development Expenses 11,044 6,648 General & Administrative Expenses 3,875 2,381 Net Loss Attributable to Common Stockholders
Slide 17: See: SELECTA
See: SELECTA